Heron reports preliminary FY2022 revenue $106.7M (+24% YoY); oncology franchise beats guidance

HERON THERAPEUTICS, INC. /DE/

2022-FY EPS reported -$1.67 revenue$107,672,000

Preliminary full-year 2022 net product sales $106.7M, up 24% YoY; oncology franchise $96.6M vs guidance $93-95M.
Q4 2022 ZYNRELEF net sales ~$3.8M, up 40% vs Q3; demand units 20,765 (+38%).
Full-year 2023 oncology franchise guidance $99-103M; APONVIE launch expected Q1 2023.
sNDA for expanded ZYNRELEF indication submitted to FDA Dec 2022; 10-month action date.
NOPAIN Act provides separate CMS reimbursement for ZYNRELEF through Dec 2027.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HERON THERAPEUTICS, INC. /DE/ reported Three and twelve months ended December 31, 2022 results: revenue The company issued a press release announcing certain of its preliminary financial results for the three and twelve mont.

Period: Three and twelve months ended December 31, 2022
Revenue: The company issued a press release announcing certain of its preliminary financial results for the three and twelve mont
Result: preliminary results

Exact text from the filing

On January 9, 2023, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain of its preliminary financial results for the three and twelve months ended December 31, 2022 (the “Press Release”).

View on SEC.gov

Browse all earnings releases →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-23-000458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.